According to All Top News -- ScienceDaily, A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue.
The available RSS description adds: In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications to show meaningful benefits…
This is a developing report. DAMMNEWS will show related coverage when closely matched reporting becomes available in the live cache.
A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications to show meaningful benefits…
DETAILS FROM THE AVAILABLE COVERAGE: These attributed excerpts expand the brief so readers can take more information from the story without opening a second summary section.
A trial chronology using only the publication times and headlines currently in the cache.
Headline comparison only — similar coverage is shown without merging sources or presenting it as one confirmed account.